2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Prostate Cancer

Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma

Reno, Nevada (UroToday.com) -- Lantheus Holdings, Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced the closing of the strategic collaboration agreements previously announced on November 14, 2022, between Lantheus and POINT Biopharma Global Inc., a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals. Closing of the agreements was subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Act.

About Lantheus

With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden.

Source: “Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with Point Biopharma.” Lantheus Holdings, Inc. Accessed December 20, 2022.